Last updated: February 15, 2026
Product Overview
Netarsudil ophthalmic solution 0.02% (NDC 80603-0105) is marketed under the brand name Rhopressa. It is indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Approved by the FDA in December 2017, Rhopressa is a Rho kinase inhibitor with a novel mechanism of action in eye health management.
Market Landscape
As of 2023, the global glaucoma drug market is valued at approximately $4.8 billion, with eye drops accounting for over 80%. The market for Rho kinase inhibitors remains nascent, comprising a few approved agents, including Rhopressa and netarsudil combinations such as Rhagayda (netarsudil + latanoprost).
Key Competitors
- Latanoprost (first-line, prostaglandin analogs)
- Timolol (beta-blockers)
- Brimonidine (alpha-adrenergic agonists)
- Other Rho kinase inhibitors (pending approval or in trials)
Rhopressa, as a first-in-class, offers a different mechanism, often used as adjunct therapy or when traditional drugs are insufficient.
Market penetration
- In 2022, Rhopressa captured roughly 5% of the American glaucoma medication market.
- Its usage is concentrated in patients resistant to traditional therapies or those requiring additional IOP control.
- Prescriptions are incrementally rising, with an annual growth rate of about 7% in the U.S.
Pricing and Revenue Estimates
- The wholesale acquisition cost (WAC) for Rhopressa is approximately $84 per bottle (2.5 mL).
- Actual patient out-of-pocket costs are typically lower, depending on insurance coverage.
- Expected annual treatment cost per patient ranges from $1,200 to $1,400.
Pricing Trends & Projections
- The initial WAC has remained stable since approval; however, discounts and insurance negotiations influence net revenue.
- Given the drug’s niche positioning, price increases are limited to inflation-related adjustments.
- The global market, especially in Europe and emerging markets, offers growth potential but faces regulatory and reimbursement hurdles.
Future Market Dynamics
- The entry of generic alternatives will pressure prices, though none are expected within the next 3-5 years due to patent protections.
- Expanding indications, such as combination therapy with other ocular hypertension agents, can expand market size.
- Ongoing clinical trials aim to assess efficacy in other ocular conditions, possibly broadening the market.
Revenue Projections (2023-2028)
| Year |
Market Share |
Estimated Prescriptions (U.S.) |
Revenue (USD millions) |
| 2023 |
5% |
250,000 |
300 |
| 2024 |
6% |
300,000 |
360 |
| 2025 |
7% |
350,000 |
420 |
| 2026 |
8% |
400,000 |
480 |
| 2027 |
9% |
450,000 |
540 |
| 2028 |
10% |
500,000 |
600 |
(Estimates based on prescription growth patterns and market expansion, adjusted for competition and market saturation.)
Regulatory and Reimbursement Factors
- Insurance coverages are favorable for branded Rhopressa, which supports stable pricing.
- Medicare Part D formulary inclusion influences patient access and revenue.
- Pending negotiations with payers could influence net prices.
Conclusion
Rhopressa faces limited competition but holds a niche position due to its mechanism and indications. Revenues are expected to grow modestly over the next five years, driven by increased adoption and expanded use cases, with stable pricing in the absence of generic competition.
Key Takeaways
- Rhopressa’s U.S. market share remains modest but is growing.
- Price stability is expected, with slight inflation-based increases.
- Market expansion depends on indication broadening and competitive dynamics.
- Revenue projections suggest steady growth to about $600 million annually by 2028.
- Regulatory and reimbursement factors support sustained pricing and access.
FAQs
-
What factors could impact Rhopressa’s market share in the coming years?
Competition from newer drugs, emerging clinical data, and shifts in treatment guidelines could influence adoption rates.
-
How might the entry of generics affect Rhopressa’s pricing?
The patent is expected to remain effective for several years, limiting generic competition; significant price erosion is unlikely before 2028.
-
Are there upcoming indications that could expand Rhopressa’s market?
Clinical trials are exploring efficacy in other ocular conditions, potentially broadening the patient base.
-
What is the typical insurance coverage for Rhopressa?
Coverage varies; Medicare and private insurers generally include it, supporting consistent revenue streams.
-
Could new competitors disrupt the Rho kinase inhibitor space?
Yes; if alternative drugs with superior efficacy or better pricing receive approval, they could challenge Rhopressa’s market positioning.
Sources
- FDA approval documentation, December 2017.
- MarketResearch.com, “Global Glaucoma Treatment Market,” 2023.
- IQVIA prescription data, 2022.
- Company financial disclosures and official pricing statements.
